Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.
Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic acid derivatives that target specific enzymes involved in cancer progression such as histone deacetylases, matrix metalloproteinases and also RNR.
Laboratory for Systems Biomedicine, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka cesta 54, 10 000, Zagreb, Croatia. nsaban@irb.hr
Nina
N
Saban
Maro
M
Bujak
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry / Q000627:therapeutic use*; D006918:Hydroxyurea / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D006918:Hydroxyurea